All In Biotech

Drug Trial Radar · NCT00629278

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS

Last checked: Nov 19, 2026Latest source record: Aug 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,500

Planned (sponsor's estimate)

Start

Dec 2007

Primary completion

Dec 2010

Sponsor

Lead sponsor
Azienda Ospedaliero-Universitaria di ModenaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known which regimen of combination chemotherapy given together with trastuzumab is most effective in treating breast cancer. PURPOSE: This randomized phase III trial is comparing two different regimens of combination chemotherapy given together with trastuzumab to see how well they work in treating women with HER2-positive stage I, stage II, or stage III breast cancer.

Conditions

  • Breast Cancer

Interventions

  • trastuzumabBiological

  • aromatase inhibition therapyDrug

  • cyclophosphamideDrug

  • docetaxelDrug

  • doxorubicin hydrochlorideDrug

  • epirubicin hydrochlorideDrug

  • fluorouracilDrug

  • paclitaxelDrug

  • releasing hormone agonist therapyDrug

  • tamoxifen citrateDrug

  • adjuvant therapyProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival
  2. Overall survival

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Ospedale Santa Croce

    Cuneo, Italy · Recruiting

  • Ospedale Civile di Ivrea

    Ivrea, Italy · Recruiting

  • Azienda Ospedaliera - Universitaria di Modena

    Modena, Italy · Recruiting

  • Piacenza Hospital

    Piacenza, Italy · Recruiting

  • Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino

    Turin, Italy · Recruiting

  • Ospedal San Andrea

    Vercelli, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.